Evidence map›Paper›PMID 41438036›Full record

ArticleiScience2025

Alexidine is a TAZ-specific small-molecule inhibitor that suppresses breast cancer invasion and metastasis.

Anni Ge, Lishui Niu, Rachel Rubino, Kimberly Seaman, Xin Song, Yawei Hao, Kody Klupt, Natasha Iaboni, Zongchao Jia, Lidan You and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Anni GeDepartment of Pathology and Molecular Medicine, Queen's University, Kingston, ON K7L 3N6, Canada.
Lishui NiuDepartment of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, GA 30322, USA.
Rachel RubinoDepartment of Pathology and Molecular Medicine, Queen's University, Kingston, ON K7L 3N6, Canada.
Kimberly SeamanDepartment of Mechanical and Industrial Engineering, University of Toronto, Toronto, ON M5S 3G9, Canada.
Xin SongDepartment of Mechanical and Industrial Engineering, University of Toronto, Toronto, ON M5S 3G9, Canada.
Yawei HaoDepartment of Pathology and Molecular Medicine, Queen's University, Kingston, ON K7L 3N6, Canada.
Kody KluptDepartment of Biomedical and Molecular Sciences, Queen's University, Kingston, ON K7L 3N6, Canada.
Natasha IaboniDepartment of Pathology and Molecular Medicine, Queen's University, Kingston, ON K7L 3N6, Canada.
Zongchao JiaDepartment of Biomedical and Molecular Sciences, Queen's University, Kingston, ON K7L 3N6, Canada.
Lidan YouDepartment of Mechanical and Industrial Engineering, University of Toronto, Toronto, ON M5S 3G9, Canada.
Christopher J B NicolDepartment of Pathology and Molecular Medicine, Queen's University, Kingston, ON K7L 3N6, Canada.
Haian FuDepartment of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, GA 30322, USA.
Yuhong DuDepartment of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, GA 30322, USA.
Xiaolong YangDepartment of Pathology and Molecular Medicine, Queen's University, Kingston, ON K7L 3N6, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer (BC) is the most diagnosed malignancy in women and often progresses to distant metastasis. Unfortunately, current treatments inadequately address the clinical needs of metastatic BC (MBC) patients. This highlights the importance of developing effective therapies for MBC patients. One of the Hippo signaling transducers, transcriptional co-activator with PDZ-binding motif (TAZ), plays a major role in BC progression. Since TAZ mostly interacts with TEAD to facilitate its function, targeting TAZ-TEAD interaction may become a treatment approach for MBC patients. To identify inhibitors of TAZ-TEAD binding, we established a sensitive TR-FRET biosensor and performed an ultra-high throughput screen. Alexidine was identified as a TAZ-TEAD binding inhibitor capable of suppressing TAZ-induced migration and invasion in BC cells as well as metastasis in bone-on-a-chip and mouse models. In conclusion, we describe a robust method for screening inhibitors of TAZ-TEAD interaction, contributing to the development of effective cancer treatments.

Indexed as

biochemistrybiological sciencescancernatural sciencespharmacology

Identifiers

PMID41438036
PMCPMC12719775

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.